Pharmaceuticals, Biotechnology and Life Sciences
FDA has approved Genentech’s Rituxan as the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis. Genetech noted that this approval is the first pediatric indication for Rituxan.
Pfizer’s study of investigational Oral JAK1 candidate in Abrocitinibfor Severe Atopic Dermatitis hits targets achieves all co-primary and key secondary endpoints, as safety results show both doses of abrocitinib consistent with prior clinical trial experiences.
National Law Firm Handling Large-Scale Freezer Failure Cases in San Francisco and Cleveland LOS ANGELES–(BUSINESS WIRE)–The failure of stem cell…
ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of…
– Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1…
Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug…
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda), which will enable Takeda…
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019…
Company appoints Flexion Therapeutics CEO Mike Clayman as board chairman DURHAM, N.C.–(BUSINESS WIRE)–Ribometrix, a biotechnology company developing small molecule therapeutics…
TORONTO & BOSTON–(BUSINESS WIRE)–Northern Biologics Inc., a company focused on developing first-in-class oncology products, today announced the presentation of updated…